Vaccines

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

iVeena promotes key execs as it prepares for clinical trials of a novel eye drop that could reshape pediatric myopia treatment worldwide.

A world-first trial for personalized mRNA vaccines offers new hope for children with aggressive brain tumors, a mission born from a father's own fight.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

A new bipartisan law injects vital funds into neuromuscular disease research, a victory driven by years of relentless patient advocacy. Here's what it means.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

Incyte's Zynyz gets a key EU panel's nod, offering a breakthrough for advanced anal canal cancer patients after decades of limited treatment options.